61 related articles for article (PubMed ID: 10353753)
1. An improved nonisotopic test to screen a large series of new inhibitor molecules of poly(ADP-ribose) polymerase activity for therapeutic applications.
Decker P; Miranda EA; de Murcia G; Muller S
Clin Cancer Res; 1999 May; 5(5):1169-72. PubMed ID: 10353753
[TBL] [Abstract][Full Text] [Related]
2. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
Putt KS; Hergenrother PJ
Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
[TBL] [Abstract][Full Text] [Related]
3. A scintillation proximity assay for poly(ADP-ribose) polymerase.
Cheung A; Zhang J
Anal Biochem; 2000 Jun; 282(1):24-8. PubMed ID: 10860495
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
Nguewa PA; Fuertes MA; Valladares B; Alonso C; Pérez JM
Prog Biophys Mol Biol; 2005 May; 88(1):143-72. PubMed ID: 15561303
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of poly(ADP-ribose) polymerase (PARP) influences the mode of sulfur mustard (SM)-induced cell death in HaCaT cells.
Kehe K; Raithel K; Kreppel H; Jochum M; Worek F; Thiermann H
Arch Toxicol; 2008 Jul; 82(7):461-70. PubMed ID: 18046540
[TBL] [Abstract][Full Text] [Related]
6. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Ratnam K; Low JA
Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors.
Gaymes TJ; Shall S; Farzaneh F; Mufti GJ
Haematologica; 2008 Dec; 93(12):1886-9. PubMed ID: 18838476
[TBL] [Abstract][Full Text] [Related]
8. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
9. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
Lewis C; Low JA
Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
[TBL] [Abstract][Full Text] [Related]
10. Modulation of poly(ADP-ribosylation) in apoptotic cells.
Ivana Scovassi A; Diederich M
Biochem Pharmacol; 2004 Sep; 68(6):1041-7. PubMed ID: 15313399
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase.
Brock WA; Milas L; Bergh S; Lo R; Szabó C; Mason KA
Cancer Lett; 2004 Mar; 205(2):155-60. PubMed ID: 15036647
[TBL] [Abstract][Full Text] [Related]
12. Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors.
Orvieto F; Branca D; Giomini C; Jones P; Koch U; Ontoria JM; Palumbi MC; Rowley M; Toniatti C; Muraglia E
Bioorg Med Chem Lett; 2009 Aug; 19(15):4196-200. PubMed ID: 19541484
[TBL] [Abstract][Full Text] [Related]
13. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
Eltze T; Boer R; Wagner T; Weinbrenner S; McDonald MC; Thiemermann C; Bürkle A; Klein T
Mol Pharmacol; 2008 Dec; 74(6):1587-98. PubMed ID: 18809672
[TBL] [Abstract][Full Text] [Related]
14. Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects.
Pogrebniak A; Schemainda I; Pelka-Fleischer R; Nüssler V; Hasmann M
Eur J Med Res; 2003 Oct; 8(10):438-50. PubMed ID: 14594650
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma.
Genovese T; Mazzon E; Muià C; Patel NS; Threadgill MD; Bramanti P; De Sarro A; Thiemermann C; Cuzzocrea S
J Pharmacol Exp Ther; 2005 Feb; 312(2):449-57. PubMed ID: 15452194
[TBL] [Abstract][Full Text] [Related]
16. Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester.
Tentori L; Balduzzi A; Portarena I; Levati L; Vernole P; Gold B; Bonmassar E; Graziani G
Cell Death Differ; 2001 Aug; 8(8):817-28. PubMed ID: 11526435
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death.
Oumouna-Benachour K; Hans CP; Suzuki Y; Naura A; Datta R; Belmadani S; Fallon K; Woods C; Boulares AH
Circulation; 2007 May; 115(18):2442-50. PubMed ID: 17438151
[TBL] [Abstract][Full Text] [Related]
18. A cellular defense pathway regulating transcription through poly(ADP-ribosyl)ation in response to DNA damage.
Vispe S; Yung TM; Ritchot J; Serizawa H; Satoh MS
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):9886-91. PubMed ID: 10944198
[TBL] [Abstract][Full Text] [Related]
19. Development of a miniaturized assay for the high-throughput screening program for poly(ADP-ribose) polymerase-1.
Lee S; Koo HN; Lee BH
Methods Find Exp Clin Pharmacol; 2005 Nov; 27(9):617-22. PubMed ID: 16357945
[TBL] [Abstract][Full Text] [Related]
20. [Poly(ADP-ribose) polymerase-1 as a regulator of protein-nucleic acid interactions in the processes responding to genotoxic action].
Sukhanova MV; Lavrik OI; Khodyreva SN
Mol Biol (Mosk); 2004; 38(5):834-47. PubMed ID: 15554186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
